Russell Investments Group
JNCE

Russell Investments Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Russell Investments Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,017
Closed -$13K – 2994
2022
Q1 		$13K Hold
2,017
– – ﹤0.01% 2701
2021
Q4 		$16K Hold
2,017
– – ﹤0.01% 2964
2021
Q3 		$14K Hold
2,017
– – ﹤0.01% 3009
2021
Q2 		$13K Sell
2,017
-33,809
-94% -$281K ﹤0.01% 3184
2021
Q1 		$367K Sell
35,826
-36,512
-50% -$400K ﹤0.01% 2643
2020
Q4 		$504K Sell
72,338
-115,792
-62% -$901K ﹤0.01% 2423
2020
Q3 		$1.53M Sell
188,130
-22,795
-11% -$141K ﹤0.01% 1854
2020
Q2 		$1.46M Sell
210,925
-19,174
-8% -$103K ﹤0.01% 1829
2020
Q1 		$1.1M Buy
230,099
+147,794
+180% +$851K ﹤0.01% 1791
2019
Q4 		$698K Buy
82,305
+48,470
+143% +$262K ﹤0.01% 2282
2019
Q3 		$113K Buy
+33,835
New +$135K ﹤0.01% 2802
2018
Q4 		– Sell
-83,478
Closed -$543K – 3063
2018
Q3 		$543K Buy
83,478
+63,512
+318% +$472K ﹤0.01% 2354
2018
Q2 		$153K Hold
19,966
– – ﹤0.01% 2692
2018
Q1 		$446K Sell
19,966
-12,258
-38% -$272K ﹤0.01% 2504
2017
Q4 		$421K Hold
32,224
– – ﹤0.01% 2490
2017
Q3 		$502K Buy
+32,224
New +$456K ﹤0.01% 2441

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Russell Investments Group's JNCE Position: Q2 2022 in Review

Russell Investments Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 2,017 shares — an estimated $13K sold.

Russell Investments Group first reported a position in JNCE in Q3 2017 and held it in 16 quarters. The position peaked at $1.53M in Q3 2020. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

  • Russell Investments Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Russell Investments Group sold 2,017 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $13K.
  • Russell Investments Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 16 quarters.
  • Russell Investments Group's Jounce Therapeutics, Inc. Common Stock position peaked at $1.53M in Q3 2020.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Russell Investments Group's 13F filing for Q2 2022, filed 29 Jul 2022.